plunged nearly 61 percent Friday on news that the Food and Drug Administration would not approve immediately a new migraine drug until further safety information is acquired. Pozen (Nasdaq: POZN) ...

Looming patent expiration on the migraine drug Treximet has led pharmaceutical company Pozen to take further legal action to fend off generic competition. The U.S. Food and Drug Administration ...

are going to make another attempt to win government approval of their proposed treatment for migraine headaches. Pozen said Monday morning that the two firms would submit a "full response" to the Food ...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it has sold most of the future ...

, a pharmaceutical company committed to transforming medicine that transforms lives, today announced the results of the Company's Type A meeting with the U.S. Food and Drug Administration (FDA) ...

NEW YORK (CBS.MW) -- Pozen pozn shares fell more than 6 percent to $13.50 after the company filed with the Securities and Exchange Commission for the sale of 8 million common shares at $11.91 each.